Currently, because KRAS-mutant lung adenocarcinoma (LUAD) is resistant to the MEK inhibitor trametinib, it has been found that trametinib in combination with ICIs for the treatment of LUAD exerts a synergistic anti-tumor effect (186). The gene discussed is KRAS; the disease is neoplasm.